HCS-Pharma is pleased to launch BIOMIMESYS® Liver and Oncology in ready-to-use 384-well plate format for screening applications. Adopt BIOMIMESYS® 3D cell culture systems and obtain more predictive in vitro models. You can find our presentations in PDF format for BIOMIMESYS® Liver for BIOMIMESYS® Oncology For more information, contact us at hello@biomimesys.com
In 2018, the World Health Organization announced 9.6 million deaths due to cancer, worldwide. Concerning the cancer cost, it was estimated to be more than US$ 1.16 trillion. For these reasons, developing more effective anti-cancer molecules is primordial. Unfortunately, despite the large number of molecules tested, 43% of failure occurs Read more…
At the occasion of the Breast Cancer Awareness Month, we would like to highlight the role of the interplay between the extracellular environment and the Cancer-Associated Fibroblasts (CAFs) on the tumoral development, including breast cancers. In our previous articles, we described the pro-tumoral effect of the extracellular environment. Moreover, an Read more…
It’s pleasure to welcome Thomas in our team. After a four-month internship at the CrCHUM (Centre de recherche du Centre Hospitalier de l’Université de Montréal, Canada) in the field of microfluidic personalized medicine for prostate cancer, he joined us in September for a six- months-internship, as part of his Master’s Read more…
This summer, Vitali et al. published an article in the Open Access Journal Cancers in which they assessed anticancer combination to treat neuroendocrine tumors (NETs) using in vitro models (2D + 3D cultures in BIOMIMESYS hydroscaffolds). A NET arises in the specialized cells of the neuroendocrine system, which have traits of Read more…
Dr. Karine Hannebicque has joined our Scientific Advisory Board. She is a surgeon in breast cancer and reconstructive surgery working in Oscar Lambret Center in the Department of breast oncology since 2013. She is also Medical Coordinator of the Ambulatory Surgery Unit since 2018. After her Internship in Obstetrics & Read more…
We are happy to tell you that HCS Pharma, SMMiL-E team (Seeding Microsystems in Medecine in Lille – European-Japanese Technologies against Cancer, CNRS UMI-2820 LIMMS/IIS) and Institut d’Electronique, de Micro-Electronique et de Nanotechnologie (IEMN) have successfully applied to a LabCom grant (‘COMmon LABoratory’)! A LabCom aims at gathering two entities Read more…
It is now well described that in tumor biopsies, the stiffness of the cancerous tissue is higher than the surrounding non-cancerous tissue of the same organ, with a described remodeling of the ECM. The increase in rigidity is related to the stimulation of fibroblasts that increase the synthesis of glycosaminoglycans, Read more…
Last week we were glad to attend TERMIS-EU workshop in Nantes, dealing with 3D bioprinting in cancer research. There we presented 3 posters – that you can find on our website! – about BIOMIMESYS® product range, about iPSC-derived hepatocytes in BIOMIMESYS® Liver, and about BIOMIMESYS® for organ-on-chip systems… Moreover, we Read more…
The extracellular matrix (ECM) is known as a molecular network of macromolecules present in all solid tissues (Figure 1), which plays an important role in the growth, migration and differentiation of cells. This ECM is part of a complex and plastic microenvironment in health and disease: its composition and physical Read more…
The 16th SFBMEC congress was held last week in Reims: Elodie and Zied attended the meeting to be aware of the last trends in extracellular matrix (ECM) research and industry and medical applications. And they were not disappointed! After a first touching lecture in memoriam of the late Ladislas Robert Read more…
Next week HCS Pharma will be present at SFBMEc Reims (15th-17th May). We will present a poster about the influence of BIOMIMESYS® hydroscaffold composition and stiffness on the 3D culture of breast cancer cells. The poster will be avalaible next week, but if you want it before, you can contact Read more…
BIOMIMESYS® Oncology is mostly composed of hyaluronic acid (HA), biofunctionnalized with undenaturated collagen I. HA, by interacting with its binding proteins (CD44, RHAMM, ICAM-1), is an active participant in inflammatory, angiogenic, fibrotic and cancer-promoting processes (Figure 1). We are currently looking at the effect of different elastic moduli of BIOMIMESYS® Read more…
Extracellular matrix (ECM) is known to have an influence on physiological processes and on tumour progression: ECM properties (composition, stiffness) modulate cell proliferation, migration, invasion and epithelial-to-mesenchymal transition (EMT). For example, EMT is inhibited by laminin-rich environment whereas it is promoted in fibronectin-rich ECM (Chen et al 2013. Differentiation 86, Read more…
In this article, researchers from Sorbonne University (Paris, France) proposed an explanation for the patterns followed by breast cancer cells when seeded in BIOMIMESYS, i.e. spherical aggregates. Usually, mathematical models dealing with the formation of patterns by cells in the extracellular matrix do not take into account the chemical environmental Read more…
The skin performs important function, including sun protection. Melanin distribution in the epidermis plays a role in photoprotection. Solar radiations induced epidermal DNA damages, mostly in the basal layer, and is an established caused of keratinocytes cancers. Melanin distribution in human epidermis is essentialy located in the basal layer. However, Read more…
Melanoma is a type of skin cancer that develops from cells called melanocytes, is one of the fastest-growing and deadliest cancer in the world. It usually caused by DNA damage resulting from exposure to ultraviolet (UV) light from the sun. P. acnes is a ubiquitous gram-positive anaerobic bacterium present in Read more…
Researchers from the Department of Dermatology of the University of California have a commensal strain of Staphylococcus epidermidis that protects against skin neoplasia. This strain produces 6-N-hydroxyaminopurine (6-HAP), a molecule that inhibits DNA polymerase activity. Mice colonized with this strain have a reduced incidence of ultraviolet-induced tumors compared to control mice (colonized with Read more…
Deep Learning et Imagerie pour dépister le cancer
Precision medicine is a new step in healthcare
A controversial study about links between tumors and genetic mutations
The conference will focus on DYRK1A, DYRK1B, 2, 3, 4 and the closely related CLKs
Quantifying DNA damage is mandatory to assess potential adverse effects of candidate drugs or molecules or extracts developed in the dermo-cosmetic industry, but also to assess the efficacy of therapeutic approaches with the aim of producing tumor cell genotoxicity in cancer treatment.